Tru-D SmartUVC Germ-Killing Robot Highlighted at SHEA Spring 2015 Science Guiding Prevention Conference

ORLANDO, Fla., May 14, 2015 /PRNewswire/ -- Tru-D SmartUVC, the most advanced and effective portable automated UV disinfection robot, is once again being highlighted through independent research.

A presentation titled "Improving Environmental Cleaning in a Community Hospital with Tru-D SmartUVC Technology," by Amy Hughes, BSN, RN, CIC, will showcase Tru-D's proven capabilities Saturday, May 16 at the Society for Healthcare Epidemiology of America (SHEA) Spring 2015 Conference in Orlando.

Short for Total Room Ultraviolet Disinfection, Tru-D "finishes the job" by bolstering the traditional disinfecting efforts of hospital staff and reducing the risk of dangerous infections being transmitted through surface contact. The remotely operated robot works from a single position within the room by delivering an automated, accurately delivered dose of UVC light that modifies the DNA structure of an infectious cell, rendering it harmless. Validated by more than 12 independent studies, Tru-D ensures a 99.99 percent pathogen reduction in direct and indirect shadowed areas and eliminates the threat of human error in the disinfection process.

The SHEA Spring 2015 Conference will focus on scientific abstracts related to patient safety, prevention strategies, health care epidemiology and surveillance, with sessions on integrating approaches involving implementation science and prevention for a variety of health care facilities.

With recent epidemic scares and an initiative from President Barack Obama to prevent the spread of antibiotic-resistant bacteria, the need for infection control and prevention heightens as hospitals look for new ways to ensure optimized and evidence-based patient safety. Tru-D SmartUVC is the world leader in robotic disinfection systems with its patented method of delivering an automated, measured dose of germicidal UVC light to consistently disinfect an entire room during a single cycle. It has the ability to safely eliminate viruses, bacteria, spores and other pathogens from rooms where patients were treated for serious and contagious diseases — including superbugs like MRSA, CRE, C. diff and even Ebola.

The robot's ultra-efficient low-pressure mercury vapor UVC lamps, endorsed by the Environmental Protection Agency and the U.S. Department of Energy for use in health care environments, provide three times the germicidal dose for every minute of operation in side-by-side comparisons with competing xenon strobe lights that claim the ability to disinfect health care spaces. Additionally, the robot's robust cloud-based data-tracking technology, iTru-D, transfers usage data to a customized portal to provide real-time results through concise graphics and exportable records. Tru-D's combined automated dose measuring capabilities and real-time usage-tracking features make Tru-D the device of choice for discerning hospitals that are looking to implement evidence-based, best-in-class technology.

"Hospitals have to be proactive in their efforts to reduce the risk of the transmission of infection and focus on delivering the safest environment possible for their patients to heal and their staff to operate in," said Chuck Dunn, president and CEO of Tru-D SmartUVC, LLC. "Using this best-in-class UV disinfection technology gives hospitals confidence in protecting their patients and staff, as well as the ability to track and optimize their infection prevention efforts."

About Tru-D SmartUVC

Tru-D SmartUVC is the device of choice for nearly all of the existing independent research on UV disinfection technology, including the most comprehensive and epidemiologically sound UV disinfection study to date – the CDC-funded Benefits of Enhanced Terminal Room (BETR) Disinfection study is slated for publication in the fall of 2015. More than 300 Tru-Ds have been deployed to disinfect hospitals across the globe, including the National Institutes of Health Clinical Center in Bethesda, Maryland; Vancouver General Hospital in Vancouver, British Columbia; Nottingham University Hospitals NHS Trust's QMC campus in Nottingham, England; and Ebola Treatment Units at ELWA Hospital and Island Hospital in Monrovia, Liberia. For information and links to independent studies on Tru-D, visit http://www.Tru-D.com.

MEDIA RELEASE  
Ali Glemser
Obsidian PR/TRU-D
901-572-1042
Email

SOURCE Tru-D

Related Links

http://tru-d.com